BridgeBio Oncology Therapeutics, Inc. (BBOT) Stock Price & Analysis
BridgeBio Oncology Therapeutics, Inc. (BBOT) closed at USD 2.95 on Thursday, October 15, 2026, up 1.55% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 2.91; the Oct 15, 2026 session ranged USD 2.86–3.1 on volume of 473,892 shares. Market capitalization is $236.51M, with a 52-week range of USD 2.86–14.87 (NGM). Source: Nexqual, retrieved October 16, 2026 at 05:19 UTC.
Also available as compact Markdown for AI agents: nexqual.com/BBOT.md
Key facts (BBOT)
- Analysts: Buy (mean 1.67 on a 1–5 scale) (12 analysts), mean target USD 24.55 (range 15–50).
- Total return with dividends: 1Y -74.1% vs S&P 500 +18.1%; 5Y -71.0% vs S&P 500 +85.1%.
- Next earnings: 2026-11-11, EPS estimate USD -0.66, revenue estimate $0K.
Analysts (BBOT)
Consensus Buy (mean 1.67 on a 1–5 scale), 12 analysts; mean target USD 24.55 (low 15, high 50).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-11 | JP Morgan | Target lowered | Overweight | $25 → $23 |
| 2026-09-10 | Leerink Partners | Target lowered | Outperform | $39 → $27 |
| 2026-09-09 | Canaccord Genuity | Target lowered | Buy | $23 → $20 |
| 2026-09-09 | Raymond James | Target lowered | Outperform | $24 → $22 |
| 2026-09-09 | Stifel | Target lowered | Buy | $23 → $15 |
| 2026-09-09 | Wedbush | Reiterated | Outperform | $25 |
| 2026-08-14 | JP Morgan | Target lowered | Overweight | $27 → $25 |
| 2026-07-08 | JP Morgan | Initiated | Overweight | $27 |
Total return (dividends reinvested) (BBOT)
| 1Y (from 2025-10-16) | 5Y (from 2024-02-05) | |
|---|---|---|
| Total return | -74.1% | -71.0% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -74.2% | -36.9% |
| Volatility (annualized) | 71.1% | 52.1% |
| Max drawdown | -78.8% (Nov 2025→Oct 2026) | -78.5% (Dec 2025→Oct 2026) |
Key Statistics (as of October 16, 2026 at 05:19 UTC)
| Price | USD 2.95 |
|---|---|
| Change | ▲ 1.55% (up) |
| Previous Close | USD 2.91 |
| Open | USD 2.9 |
| Day Range | USD 2.86 – 3.1 |
| 52-Week Range | USD 2.86 – 14.87 |
| Volume | 473,892 shares |
| Market Cap | $236.51M |
| Exchange | NGM |
Technical Analysis (BBOT)
Nexqual's technical model rates BBOT "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:19 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 11.48 (oversold) |
| vs SMA50 | Below (USD 6.42) |
| MACD | -0.92 (negative) |
Analyst Ratings (BBOT)
Wall Street analysts rate BBOT "Buy" based on 12 analysts, with a mean price target of USD 24.55 (range USD 15–50), per Nexqual as of October 16, 2026 at 05:19 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 12 |
| Mean Target | USD 24.55 |
| High Target | USD 50 |
| Low Target | USD 15 |
| Buy / Hold / Sell | 12 / 0 / 0 |
Earnings (BBOT)
| Next Earnings Date | 2026-11-11 |
|---|---|
| EPS Estimate | USD -0.66 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.71 vs est -0.54 ▼ miss |
| 2025-12-31 | USD -0.49 vs est -0.66 ▲ beat |
| 2025-09-30 | USD -1.03 vs est -0.34 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financials & Fundamentals (BBOT)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -81.92% |
| Debt / Equity | 0.01 |
| Current Ratio | 4.69 |
| Total Cash | $225.71M |
| Total Debt | $2.51M |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financial Health Score (BBOT)
Nexqual rates BridgeBio Oncology Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:19 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $226M cash vs $3M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$151M (TTM) |
| Efficiency | Critical — ROE -82%, ROA -47.1% |
Ownership (BBOT)
| Insider Ownership | +27.12% |
|---|---|
| Institutional Ownership | +71.05% |
| Shares Outstanding | 80.17M |
| Float | 35.81M |
| Short % of Float | +11.82% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Leadership (BBOT)
BridgeBio Oncology Therapeutics, Inc. is led by Pedro J. Beltran (age 54), Chief Executive Officer and Director, per Nexqual as of October 16, 2026 at 05:19 UTC.
| Chief Executive Officer and Director | Pedro J. Beltran (age 54) |
|---|---|
| Executive Chairman | Neil Kumar (age 46) |
| Co-Founder, Non-Executive Director & Chair of the Advisory Board | Frank P. McCormick (age 75) |
| Chief Operating Officer | Idan Elmelech M.A. (age 32) |
| Vice President of Legal | Aaron Chan |
Major Backers & Investors (BBOT)
Notable institutional backers of BridgeBio Oncology Therapeutics, Inc. include Cormorant Asset Management, LP, Deerfield Management Company, L.P, Omega Fund Management, Llc, according to Nexqual as of October 16, 2026 at 05:19 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Cormorant Asset Management, LP | 22.3% |
| Deerfield Management Company, L.P | 6.09% |
| Omega Fund Management, Llc | 4.1% |
| Alphabet Inc. | 3.52% |
| EcoR1 Capital, LLC | 3.52% |
| Wellington Management | 3.48% |
| Enavate Sciences Gp, LLC | 3.28% |
| Citadel | 3.27% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 4.52% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:19 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt